25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LAVI (Lavipharm) Stock Analysis
Buy, Hold or Sell?

Let's analyze Lavipharm together

I guess you are interested in Lavipharm S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Lavipharm’s Financial Insights
  • 📈 Technical Analysis (TA) – Lavipharm’s Price Targets

I'm going to help you getting a better view of Lavipharm S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lavipharm S.A

I send you an email if I find something interesting about Lavipharm S.A.

1. Quick Overview

1.1. Quick analysis of Lavipharm (30 sec.)










1.2. What can you expect buying and holding a share of Lavipharm? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.31
Expected worth in 1 year
€0.55
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
€0.24
Return On Investment
28.4%

For what price can you sell your share?

Current Price per Share
€0.85
Expected price per share
€0.779 - €0.866
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lavipharm (5 min.)




Live pricePrice per Share (EOD)
€0.85
Intrinsic Value Per Share
€-1.12 - €-1.33
Total Value Per Share
€-0.81 - €-1.01

2.2. Growth of Lavipharm (5 min.)




Is Lavipharm growing?

Current yearPrevious yearGrowGrow %
How rich?$62.1m$50.1m$11.9m19.3%

How much money is Lavipharm making?

Current yearPrevious yearGrowGrow %
Making money$10.5m$2.1m$8.3m79.2%
Net Profit Margin17.0%3.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Lavipharm (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lavipharm?

Welcome investor! Lavipharm's management wants to use your money to grow the business. In return you get a share of Lavipharm.

First you should know what it really means to hold a share of Lavipharm. And how you can make/lose money.

Speculation

The Price per Share of Lavipharm is €0.849. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lavipharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lavipharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.31. Based on the TTM, the Book Value Change Per Share is €0.06 per quarter. Based on the YOY, the Book Value Change Per Share is €0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lavipharm.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.067.3%0.067.3%0.011.5%0.033.2%0.022.5%0.022.6%
Usd Book Value Change Per Share0.078.3%0.078.3%0.022.0%0.1517.1%0.0911.0%0.078.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.078.3%0.078.3%0.022.0%0.1517.1%0.0911.0%0.078.3%
Usd Price Per Share0.93-0.93-0.93-0.77-0.71-0.44-
Price to Earnings Ratio14.96-14.96-71.92-54.90-51.91-28.83-
Price-to-Total Gains Ratio13.18-13.18-54.00-22.82-29.55-21.69-
Price to Book Ratio2.54-2.54-3.15-2.43--1.81--1.50-
Price-to-Total Gains Ratio13.18-13.18-54.00-22.82-29.55-21.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.9960468
Number of shares1003
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.070.09
Usd Total Gains Per Share0.070.09
Gains per Quarter (1003 shares)70.9793.79
Gains per Year (1003 shares)283.90375.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102842740375365
205685580750740
30852842011251115
4011361126015011490
5014191410018761865
6017031694022512240
7019871978026262615
8022712262030012990
9025552546033763365
10028392830037523740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%9.02.00.081.8%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%9.02.00.081.8%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%9.02.00.081.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lavipharm S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0600.0600%0.015+309%0.124-51%0.080-24%0.060+0%
Book Value Per Share--0.3130.3130%0.253+24%0.268+17%0.135+133%-0.021+107%
Current Ratio--1.1501.1500%1.275-10%1.141+1%1.156-1%1.006+14%
Debt To Asset Ratio--0.5780.5780%0.627-8%0.618-6%0.857-33%1.193-52%
Debt To Equity Ratio--1.3691.3690%1.685-19%1.629-16%0.978+40%0.489+180%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--61871980.00061871980.0000%62543024.000-1%44560300.000+39%37825620.000+64%-9325299.560+115%
Eps--0.0530.0530%0.011+380%0.023+131%0.018+190%0.019+184%
Ev To Sales Ratio--1.1691.1690%1.307-11%0.892+31%0.820+43%-0.550+147%
Free Cash Flow Per Share---0.030-0.0300%-0.022-25%-0.081+173%-0.044+50%-0.044+50%
Free Cash Flow To Equity Per Share---0.030-0.0300%-0.022-25%0.015-292%0.009-414%0.009-414%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.327----------
Intrinsic Value_10Y_min---1.120----------
Intrinsic Value_1Y_max---0.092----------
Intrinsic Value_1Y_min---0.090----------
Intrinsic Value_3Y_max---0.308----------
Intrinsic Value_3Y_min---0.291----------
Intrinsic Value_5Y_max---0.562----------
Intrinsic Value_5Y_min---0.513----------
Market Cap143518356.000+6%134389980.000134389980.0000%134559024.0000%111287300.000+21%102271620.000+31%63815800.440+111%
Net Profit Margin--0.1700.1700%0.039+334%0.076+124%0.066+159%0.078+118%
Operating Margin----0%-0%0.029-100%0.068-100%0.056-100%
Operating Ratio--1.4231.4230%1.441-1%1.464-3%1.458-2%1.357+5%
Pb Ratio2.710+6%2.5372.5370%3.146-19%2.432+4%-1.806+171%-1.504+159%
Pe Ratio15.978+6%14.96214.9620%71.918-79%54.905-73%51.912-71%28.827-48%
Price Per Share0.849+6%0.7950.7950%0.7960%0.658+21%0.605+31%0.378+111%
Price To Free Cash Flow Ratio-28.681-7%-26.857-26.8570%-35.739+33%-21.536-20%7.589-454%3.795-808%
Price To Total Gains Ratio14.076+6%13.18113.1810%53.996-76%22.823-42%29.552-55%21.694-39%
Quick Ratio--0.3990.3990%0.606-34%0.593-33%0.630-37%0.609-35%
Return On Assets--0.0720.0720%0.016+339%0.032+126%0.034+110%0.059+22%
Return On Equity--0.1700.1700%0.044+287%0.078+117%0.047+262%0.023+624%
Total Gains Per Share--0.0600.0600%0.015+309%0.124-51%0.080-24%0.060+0%
Usd Book Value--62139711.20062139711.2000%50177764.000+24%53190541.600+17%26695931.360+133%-4261179.720+107%
Usd Book Value Change Per Share--0.0710.0710%0.017+309%0.146-51%0.094-24%0.071+0%
Usd Book Value Per Share--0.3680.3680%0.297+24%0.315+17%0.158+133%-0.025+107%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--72588206.93672588206.9360%73375475.757-1%52278143.960+39%44377017.384+64%-10940441.444+115%
Usd Eps--0.0620.0620%0.013+380%0.027+131%0.022+190%0.022+184%
Usd Free Cash Flow---5870692.800-5870692.8000%-4417098.000-25%-16048984.933+173%-8792664.720+50%-4396332.360-25%
Usd Free Cash Flow Per Share---0.035-0.0350%-0.026-25%-0.095+173%-0.052+50%-0.052+50%
Usd Free Cash Flow To Equity Per Share---0.035-0.0350%-0.026-25%0.018-292%0.011-414%0.011-414%
Usd Market Cap168375735.259+6%157666324.536157666324.5360%157864646.9570%130562260.360+21%119985064.584+31%74868697.076+111%
Usd Price Per Share0.996+6%0.9330.9330%0.9340%0.772+21%0.710+31%0.443+111%
Usd Profit--10537682.40010537682.4000%2195057.200+380%4570396.133+131%3654518.000+188%3714585.840+184%
Usd Revenue--62116247.20062116247.2000%56123541.600+11%57405067.067+8%52595259.920+18%44712059.840+39%
Usd Total Gains Per Share--0.0710.0710%0.017+309%0.146-51%0.094-24%0.071+0%
 EOD+5 -3MRQTTM+0 -0YOY+20 -153Y+25 -115Y+23 -1310Y+26 -10

3.3 Fundamental Score

Let's check the fundamental score of Lavipharm S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.978
Price to Book Ratio (EOD)Between0-12.710
Net Profit Margin (MRQ)Greater than00.170
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.399
Current Ratio (MRQ)Greater than11.150
Debt to Asset Ratio (MRQ)Less than10.578
Debt to Equity Ratio (MRQ)Less than11.369
Return on Equity (MRQ)Greater than0.150.170
Return on Assets (MRQ)Greater than0.050.072
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Lavipharm S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.844
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Lavipharm S.A

Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.

Fundamental data was last updated by Penke on 2025-09-15 02:54:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lavipharm earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 17.0% means that €0.17 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lavipharm S.A:

  • The MRQ is 17.0%. The company is making a huge profit. +2
  • The TTM is 17.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ17.0%TTM17.0%0.0%
TTM17.0%YOY3.9%+13.1%
TTM17.0%5Y6.6%+10.4%
5Y6.6%10Y7.8%-1.2%
4.3.1.2. Return on Assets

Shows how efficient Lavipharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • 7.2% Return on Assets means that Lavipharm generated €0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lavipharm S.A:

  • The MRQ is 7.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY1.6%+5.5%
TTM7.2%5Y3.4%+3.7%
5Y3.4%10Y5.9%-2.5%
4.3.1.3. Return on Equity

Shows how efficient Lavipharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • 17.0% Return on Equity means Lavipharm generated €0.17 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lavipharm S.A:

  • The MRQ is 17.0%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 17.0%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ17.0%TTM17.0%0.0%
TTM17.0%YOY4.4%+12.6%
TTM17.0%5Y4.7%+12.3%
5Y4.7%10Y2.3%+2.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lavipharm S.A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lavipharm is operating .

  • Measures how much profit Lavipharm makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lavipharm S.A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y6.8%-6.8%
5Y6.8%10Y5.6%+1.1%
4.3.2.2. Operating Ratio

Measures how efficient Lavipharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are €1.42 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Lavipharm S.A:

  • The MRQ is 1.423. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.423. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.423TTM1.4230.000
TTM1.423YOY1.441-0.018
TTM1.4235Y1.458-0.035
5Y1.45810Y1.357+0.101
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lavipharm S.A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lavipharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.15 means the company has €1.15 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Lavipharm S.A:

  • The MRQ is 1.150. The company is just able to pay all its short-term debts.
  • The TTM is 1.150. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.150TTM1.1500.000
TTM1.150YOY1.275-0.125
TTM1.1505Y1.156-0.006
5Y1.15610Y1.006+0.151
4.4.3.2. Quick Ratio

Measures if Lavipharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.40 means the company can pay off €0.40 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lavipharm S.A:

  • The MRQ is 0.399. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.399. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.399TTM0.3990.000
TTM0.399YOY0.606-0.207
TTM0.3995Y0.630-0.231
5Y0.63010Y0.609+0.021
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lavipharm S.A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lavipharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lavipharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.58 means that Lavipharm assets are financed with 57.8% credit (debt) and the remaining percentage (100% - 57.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lavipharm S.A:

  • The MRQ is 0.578. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.578. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.578TTM0.5780.000
TTM0.578YOY0.627-0.049
TTM0.5785Y0.857-0.279
5Y0.85710Y1.193-0.336
4.5.4.2. Debt to Equity Ratio

Measures if Lavipharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 136.9% means that company has €1.37 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lavipharm S.A:

  • The MRQ is 1.369. The company is able to pay all its debts with equity. +1
  • The TTM is 1.369. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.369TTM1.3690.000
TTM1.369YOY1.685-0.316
TTM1.3695Y0.978+0.391
5Y0.97810Y0.489+0.489
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Lavipharm generates.

  • Above 15 is considered overpriced but always compare Lavipharm to the  Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 14.96 means the investor is paying €14.96 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lavipharm S.A:

  • The EOD is 15.978. Based on the earnings, the company is fair priced.
  • The MRQ is 14.962. Based on the earnings, the company is underpriced. +1
  • The TTM is 14.962. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD15.978MRQ14.962+1.016
MRQ14.962TTM14.9620.000
TTM14.962YOY71.918-56.956
TTM14.9625Y51.912-36.950
5Y51.91210Y28.827+23.085
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lavipharm S.A:

  • The EOD is -28.681. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -26.857. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -26.857. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.681MRQ-26.857-1.824
MRQ-26.857TTM-26.8570.000
TTM-26.857YOY-35.739+8.883
TTM-26.8575Y7.589-34.446
5Y7.58910Y3.795+3.795
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lavipharm is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Lavipharm S.A:

  • The EOD is 2.710. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.537. Based on the equity, the company is underpriced. +1
  • The TTM is 2.537. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.710MRQ2.537+0.172
MRQ2.537TTM2.5370.000
TTM2.537YOY3.146-0.609
TTM2.5375Y-1.806+4.343
5Y-1.80610Y-1.504-0.302
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Tax Provision  1,211-1921,0192911,310-621,248-6,308-5,060



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets125,484
Total Liabilities72,518
Total Stockholder Equity52,976
 As reported
Total Liabilities 72,518
Total Stockholder Equity+ 52,976
Total Assets = 125,484

Assets

Total Assets125,484
Total Current Assets45,000
Long-term Assets80,484
Total Current Assets
Cash And Cash Equivalents 5,589
Net Receivables 15,607
Inventory 19,460
Total Current Assets  (as reported)45,000
Total Current Assets  (calculated)40,656
+/- 4,344
Long-term Assets
Property Plant Equipment 21,358
Intangible Assets 49,679
Long-term Assets Other 1
Long-term Assets  (as reported)80,484
Long-term Assets  (calculated)71,038
+/- 9,446

Liabilities & Shareholders' Equity

Total Current Liabilities39,125
Long-term Liabilities33,393
Total Stockholder Equity52,976
Total Current Liabilities
Short Long Term Debt 10,566
Accounts payable 8,429
Other Current Liabilities -1
Total Current Liabilities  (as reported)39,125
Total Current Liabilities  (calculated)18,994
+/- 20,131
Long-term Liabilities
Long term Debt 12,172
Capital Lease Obligations Min Short Term Debt11,078
Long-term Liabilities Other 3,141
Long-term Liabilities  (as reported)33,393
Long-term Liabilities  (calculated)26,391
+/- 7,002
Total Stockholder Equity
Total Stockholder Equity (as reported)52,976
Total Stockholder Equity (calculated)0
+/- 52,976
Other
Capital Stock50,607
Net Debt 17,149
Net Invested Capital 75,714
Net Working Capital 5,875
Property Plant and Equipment Gross 42,247



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
> Total Assets 
83,824
82,379
48,177
44,808
41,897
49,422
50,638
52,741
114,168
114,786
125,484
125,484114,786114,16852,74150,63849,42241,89744,80848,17782,37983,824
   > Total Current Assets 
19,818
20,988
21,267
19,866
18,941
21,085
23,342
25,961
45,600
45,652
45,000
45,00045,65245,60025,96123,34221,08518,94119,86621,26720,98819,818
       Cash And Cash Equivalents 
2,437
2,057
1,675
2,348
1,842
1,732
1,932
1,638
18,243
8,435
5,589
5,5898,43518,2431,6381,9321,7321,8422,3481,6752,0572,437
       Short-term Investments 
0
0
0
44
12
0
0
0
1
3
0
0310001244000
       Net Receivables 
12,249
12,945
13,511
11,294
11,617
12,298
9,883
15,665
17,130
21,697
15,607
15,60721,69717,13015,6659,88312,29811,61711,29413,51112,94512,249
       Inventory 
3,525
4,358
5,527
5,590
4,842
6,063
8,419
9,240
10,436
14,834
19,460
19,46014,83410,4369,2408,4196,0634,8425,5905,5274,3583,525
       Other Current Assets 
1,607
1,628
453
590
628
949
769
635
960
1
0
019606357699496285904531,6281,607
   > Long-term Assets 
0
0
0
0
0
0
27,156
26,780
68,568
69,134
80,484
80,48469,13468,56826,78027,156000000
       Property Plant Equipment 
23,024
22,404
18,595
15,276
15,329
17,188
16,422
17,488
17,099
19,543
21,358
21,35819,54317,09917,48816,42217,18815,32915,27618,59522,40423,024
       Long Term Investments 
225
132
0
0
0
0
0
0
0
0
0
000000000132225
       Intangible Assets 
9,684
8,639
2,889
3,096
2,667
3,413
3,492
3,136
46,195
44,542
49,679
49,67944,54246,1953,1363,4923,4132,6673,0962,8898,6399,684
       Long-term Assets Other 
0
0
0
0
0
0
855
827
650
1
1
11650827855000000
> Total Liabilities 
132,788
146,799
80,002
64,727
61,426
63,824
62,941
62,678
73,890
72,016
72,518
72,51872,01673,89062,67862,94163,82461,42664,72780,002146,799132,788
   > Total Current Liabilities 
78,765
87,053
41,905
19,497
14,666
17,355
18,803
23,232
45,740
35,801
39,125
39,12535,80145,74023,23218,80317,35514,66619,49741,90587,05378,765
       Short-term Debt 
31,696
40,502
60
1,111
539
1,239
1,133
1,404
0
0
0
0001,4041,1331,2395391,1116040,50231,696
       Short Long Term Debt 
31,696
40,502
60
1,111
1,036
0
3,537
21,291
21,604
7,993
10,566
10,5667,99321,60421,2913,53701,0361,1116040,50231,696
       Accounts payable 
4,040
5,207
2,125
2,215
2,575
4,036
2,742
4,162
6,304
9,955
8,429
8,4299,9556,3044,1622,7424,0362,5752,2152,1255,2074,040
       Other Current Liabilities 
9,894
7,697
6,953
5,644
4,206
4,386
4,124
4,223
-1
1
-1
-11-14,2234,1244,3864,2065,6446,9537,6979,894
   > Long-term Liabilities 
0
0
0
0
0
0
43,336
21,612
28,115
36,215
33,393
33,39336,21528,11521,61243,336000000
       Long term Debt Total 
0
0
0
0
0
0
35,127
32,568
14,945
0
0
0014,94532,56835,127000000
       Capital Lease Obligations Min Short Term Debt
-31,696
-40,502
-60
-1,111
-539
-1,239
10,031
10,529
11,505
11,683
11,078
11,07811,68311,50510,52910,031-1,239-539-1,111-60-40,502-31,696
       Other Liabilities 
5,630
8,269
6,427
5,476
8,237
8,701
7,847
6,337
0
0
0
0006,3377,8478,7018,2375,4766,4278,2695,630
       Deferred Long Term Liability 
21,383
21,622
1,281
1,080
817
952
1,334
1,825
0
0
0
0001,8251,3349528171,0801,28121,62221,383
> Total Stockholder Equity
-25,997
-35,849
-31,825
-19,919
-19,529
-14,402
-12,303
-9,976
40,278
42,737
52,976
52,97642,73740,278-9,976-12,303-14,402-19,529-19,919-31,825-35,849-25,997
   Common Stock
51,081
51,081
51,081
51,081
51,081
51,081
51,081
51,081
50,361
0
0
0050,36151,08151,08151,08151,08151,08151,08151,08151,081
   Retained Earnings -23,850-32,591-17,496-159,959-161,682-164,277-169,604-169,907-160,385-180,716-173,642
   Capital Surplus 
0
0
84,418
84,418
84,418
84,418
84,418
84,418
7,413
0
0
007,41384,41884,41884,41884,41884,41884,41800
   Treasury Stock00000000000
   Other Stockholders Equity 
12,146
9,368
-6,939
14,489
14,576
14,376
14,508
14,484
0
0
0
00014,48414,50814,37614,57614,489-6,9399,36812,146



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue52,946
Cost of Revenue-27,868
Gross Profit25,07925,078
 
Operating Income (+$)
Gross Profit25,079
Operating Expense-47,473
Operating Income5,474-22,394
 
Operating Expense (+$)
Research Development631
Selling General Administrative9,456
Selling And Marketing Expenses-
Operating Expense47,47310,087
 
Net Interest Income (+$)
Interest Income146
Interest Expense-2,011
Other Finance Cost-69
Net Interest Income-1,934
 
Pretax Income (+$)
Operating Income5,474
Net Interest Income-1,934
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,6045,474
EBIT - interestExpense = -2,011
8,982
10,993
Interest Expense2,011
Earnings Before Interest and Taxes (EBIT)-5,615
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,604
Tax Provision--5,060
Net Income From Continuing Ops8,6648,664
Net Income8,982
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,934
 

Technical Analysis of Lavipharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lavipharm. The general trend of Lavipharm is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lavipharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Lavipharm Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lavipharm S.A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.865 < 0.865 < 0.866.

The bearish price targets are: 0.784 > 0.779 > 0.779.

Know someone who trades $LAVI? Share this with them.👇

Lavipharm S.A Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lavipharm S.A. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lavipharm S.A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lavipharm S.A.

Lavipharm S.A Daily Moving Average Convergence/Divergence (MACD) ChartLavipharm S.A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lavipharm S.A. The current adx is .

Lavipharm S.A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lavipharm S.A.

Lavipharm S.A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lavipharm S.A.

Lavipharm S.A Daily Relative Strength Index (RSI) ChartLavipharm S.A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lavipharm S.A.

Lavipharm S.A Daily Stochastic Oscillator ChartLavipharm S.A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lavipharm S.A.

Lavipharm S.A Daily Commodity Channel Index (CCI) ChartLavipharm S.A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lavipharm S.A.

Lavipharm S.A Daily Chande Momentum Oscillator (CMO) ChartLavipharm S.A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lavipharm S.A.

Lavipharm S.A Daily Williams %R ChartLavipharm S.A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lavipharm S.A.

Lavipharm S.A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lavipharm S.A.

Lavipharm S.A Daily Average True Range (ATR) ChartLavipharm S.A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lavipharm S.A.

Lavipharm S.A Daily On-Balance Volume (OBV) ChartLavipharm S.A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lavipharm S.A.

Lavipharm S.A Daily Money Flow Index (MFI) ChartLavipharm S.A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lavipharm S.A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Lavipharm S.A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lavipharm S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.844
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lavipharm with someone you think should read this too:
  • Are you bullish or bearish on Lavipharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lavipharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lavipharm S.A

I send you an email if I find something interesting about Lavipharm S.A.


Comments

How you think about this?

Leave a comment

Stay informed about Lavipharm S.A.

Receive notifications about Lavipharm S.A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.